EUVIMEDEUVIMED entdecken
Open Access

MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity

Justus M Huelse iD, Swati S Bhasin iD, Kristen M Jacobsen, Juhye Yim iD, Beena E Thomas, Gianna M Branella, Mojtaba Bakhtiari, Madison L Chimenti, Travon A Baxter, Sunil S Raikar iD, Xiaodong Wang, Stephen V Frye iD und 5 weitere

Leukemia · 2024

DOI: 10.1038/s41375-024-02408-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2024. Verfasst von Justus M Huelse und 16 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA. Hauptthemen laut MEDLINE: c-Mer Tyrosine Kinase, Dendritic Cells, Receptor Protein-Tyrosine Kinases, Tumor Microenvironment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TAM-family tyrosine kinases (TYRO3, AXL and MERTK) are potential cancer therapeutic targets. In previous studies MERTK inhibition in the immune microenvironment was therapeutically effective in a B-cell acute leukemia (B-ALL) model. Here, we probed anti-leukemia immune mechanisms and evaluated roles for TYRO3 and AXL in the leukemia microenvironment. Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells (DCs) with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis. High MERTK or low DC gene expression were associated with poor prognosis in pediatric ALL patients, indicating the clinical relevance of these findings. MRX-2843 increased CD8+ T-cell numbers and prevented induction of exhaustion markers, implicating a DC - T-cell axis. Indeed, combined depletion of CD8α+ DCs and CD8+ T-cells was required to abrogate anti-leukemia immunity in Mertk-/- mice. Tyro3-/- mice were also protected against B-ALL, implicating TYRO3 as an immunotherapeutic target. In contrast to Mertk-/- mice, Tyro3-/- did not increase CD8α+ DCs with enhanced antigen-presentation capacity and therapeutic activity was less dependent on DCs, indicating a different immune mechanism. Axl-/- did not impact leukemogenesis. These data demonstrate differential TAM kinase roles in the leukemia microenvironment and provide rationale for development of MERTK and/or TYRO3-targeted immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

c-Mer Tyrosine KinaseDendritic CellsReceptor Protein-Tyrosine KinasesTumor MicroenvironmentMice, KnockoutCD8-Positive T-LymphocytesAnimalsMiceHumansMice, Inbred C57BLAxl Receptor Tyrosine KinaseLeukemia

Substanzen

c-Mer Tyrosine KinaseReceptor Protein-Tyrosine KinasesMERTK protein, humanMertk protein, mouseAxl Receptor Tyrosine Kinase

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA.
  • Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 27599, USA.
  • Department of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
  • Departments of Medicine and Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Cancer Immunology Program, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.

ORCID-Profile: Justus M Huelse, Swati S Bhasin, Juhye Yim, Sunil S Raikar, Stephen V Frye, Deborah DeRyckere, Douglas K Graham

Förderung

  • NCI NIH HHS
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)

Zitieren

APA

Huelse, J. M., Bhasin, S. S., Jacobsen, K. M., Yim, J., Thomas, B. E., Branella, G. M., Bakhtiari, M., Chimenti, M. L., Baxter, T. A., Raikar, S. S., Wang, X., Frye, S. V., Henry, C. J., Earp, H. S., Bhasin, M., DeRyckere, D., & Graham, D. K. (2024). MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity. Leukemia. https://doi.org/10.1038/s41375-024-02408-2

Vancouver

Huelse JM, Bhasin SS, Jacobsen KM, Yim J, Thomas BE, Branella GM, et al. MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity. Leukemia. 2024. doi:10.1038/s41375-024-02408-2

BibTeX
@article{Huelse2024,
  author = {Huelse, Justus M and Bhasin, Swati S and Jacobsen, Kristen M and Yim, Juhye and Thomas, Beena E and Branella, Gianna M and Bakhtiari, Mojtaba and Chimenti, Madison L and Baxter, Travon A and Raikar, Sunil S and Wang, Xiaodong and Frye, Stephen V and Henry, Curtis J and Earp, H Shelton and Bhasin, Manoj and DeRyckere, Deborah and Graham, Douglas K},
  title = {MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity},
  journal = {Leukemia},
  year = {2024},
  doi = {10.1038/s41375-024-02408-2}
}
Kostenlos starten →